A prospective, multicenter, randomized, open-label, parallel group trial compared the efficacy of cyclosporine A 2.5 mg/kg/day with mycophenolate mofetil 1 g b.i.d. for 12 weeks in 54 patients with chronic plaque-type psoriasis. The Psoriasis Area and Severity Index (PASI) was used to assess psoriatic severity and the primary outcome measure was the time to disease relapse. There was no difference in time to relapse between the two groups. However PASI scores fell significantly more in the cyclosporine A group than the mycophenolate mofetil group (P = 0.02), and the relative reduction in the PASI score was 79 and 49% I the cyclosporine A and mycophenolate mofetil groups, respectively (P = 0.004). ...